Attached files
| file | filename |
|---|---|
| EX-23.1 - EX-23.1 - Zyla Life Sciences | eglt-20161231ex23199d519.htm |
| EX-10.29 - EX-10.29 - Zyla Life Sciences | eglt-20161231ex102994fbf.htm |
| EX-32.1 - EX-32.1 - Zyla Life Sciences | eglt-20161231ex321df081f.htm |
| EX-10.30 - EX-10.30 - Zyla Life Sciences | eglt-20161231ex10304c668.htm |
| EX-31.2 - EX-31.2 - Zyla Life Sciences | eglt-20161231ex312b7ed20.htm |
| EX-21.1 - EX-21.1 - Zyla Life Sciences | eglt-20161231ex2111cb5a9.htm |
| EX-32.2 - EX-32.2 - Zyla Life Sciences | eglt-20161231ex322c8bd40.htm |
| 10-K - 10-K - Zyla Life Sciences | eglt-20161231x10k.htm |
| EX-31.1 - EX-31.1 - Zyla Life Sciences | eglt-20161231ex311ba5422.htm |
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-3 (File Nos. 333-202807, and 333-209367) and in the Registration Statements on Form S-8 (File Nos. 333-212298, 333-212297, 333-204987, and 333-194946) of Egalet Corporation of our report dated March 13, 2017, with respect to the consolidated financial statements of Egalet Corporation included in this Annual Report of Egalet Corporation (Form 10-K) for the year ended December 31, 2016.
|
|
|
|
|
|
|
|
/s/ Ernst & Young LLP |
Philadelphia, Pennsylvania
March 13, 2017